Member Info for Kingalf

Extract from the company circular dated 26th January
The effect of the Share Consolidation will be to reduce the number of Existing Ordinary Shares in issue by approximately the same proportion of market capitalisation returned via the special dividend (for these purposes, the market capitalisation used is that as at market close on 22 January 2021). It is anticipated, therefore, that the market price of each Ordinary Share in the Company should remain at a broadly similar level following the Special Dividend and the Share Consolidation
In other words the dividend will be offset by an equivalent reduction in shares, this will result in NO change to the share price come Monday.
In addition, I hope no one buying recently was thinking they were getting a free lunch by way of the 0.509p dividend.
If you purchased these outside an isa wrapper, don't forget any dividends you recieve over £2000 ( including any from your other investments this tax year) will incur a tax liability which will put you at an instant loss come Monday.

SuperSonicBoom - just for clarity is that Braveheart inv grp

Say you own 8246 shares x price £2.40 = £19,790
Your holding will then reduce to 6510 shares x price £2.40 = £15,624.
In return you will receive 0.509p per share x 8246 = £4197 which just about equates to the loss incurred by the consolidation.
As far as I can see Tesco has been in a range of 2.45 to 2.04 over the last 6 months, apart from adding 2.5b to the pension fund and following on from the share consolidation nothing else will have changed. Personally feel these could quite easily test the lower end of the band again, unless you feel adding 2.5bn to the pension pot is enough to justify a £3 share price.

So much has been made of this supposed magic number of 100. Its almost as if some on here think the medicine has already been proved to work, but the only thing holding this back is the recruitment process .
Wake up people, the promised land is a long way off and going by previous experience with this company, the chances of getting there are very slim.

Probably the likes of Richard Griffiths, who were given the nod of a share placing months ago, sold a percentage at around 12 to 14p and will now look to replace the sold stock at 8p.
It is just an illusion that you have all these major players joining the party, the reality is that the over subscription is basically down to the so called major player repositioning themselves at a lower price all to the detriment to the ordinary share holder.

The technicals look dire, Schroders unwinding and the threat of expulsion from ft100 we could well test the support at 1.64p.
Long term they are a massive buy, short term is looking a little uncertain and could well present a great buying opportunity.

Mrshoubs - I've been dipping in and out of this over the last six months.
Last position was taken out on 10th Nov at 7.89p and I existed a couple of weeks ago at 10.89p.
I tend to follow Moneymunch, when he goes quiet I look to buy, when his Ramping is in overdrive as it is now I look to sell.
Seems to work for me.
Google Avoid Aim Traps, its an article by the Investors Chronicle. It is striking as to how many parallels there are with Evgen. Even Moneymunch gets an indirect mention under title
Online bulletin boards.

This one is for you SuperSonicBoom we seem to understand each other

Placings leaked

Another risk of placings is that they are leaked. This helps nobody, as people sell, which drives the share price lower, which inevitably means that those providing the fundraising will want a bigger discount. Those who leak placings often claim that they are making everything fair for everyone – but those who are really hurt are the company’s actual shareholders. It’s value destruction with no upside.

One way to improve this would be to suspend the stock as soon as market soundings begin. The Australian exchange already does this, and many wish for it to be implemented in London too. Sadly, Aim is stuck in the paleolithic age when it comes to enforcing regulation, and so placings will continue to be leaked and value will continue to be destroyed.

Many people suspect that a broker will go short on a company, and then offer that same company cash through a placing. The broker then closes its short in the placing, and they are incentivised to offer as low a price as possible to maximise their own profit.

This extract was also very appropriate

Placings

Equity raises are a necessary evil on Aim, as ‘growth’ companies often require cash to develop projects and invest in the business. However, many of these companies are not growth companies, but lifestyle vehicles for the directors. What may start out as an exciting dream to build a business eventually ends up in failure, but the directors have then become accustomed to increasingly higher salaries despite the share price going increasingly lower. A turkey doesn’t vote for Christmas – and so they hold on to their positions as long as they can. All of this, of course, is funded by the retail investor.

The company is a vehicle that pays the directors' salaries. It also pays the Nomad. It pays the broker (which may also be the Nomad), and it pays the PR agency. All of these parties, including the directors, have an interest in the company continuing, because without it they are all out of jobs. Therefore, there is always a new story or a new project to invest in – so long as retail investors continue to fund story stocks then the company will continue. If you are going to invest, it’s worth checking how much the directors have taken out of the business and how much of their own capital they’ve put in. Nil-cost options do not count – this is simply transferring shareholder cash into the directors’ pockets.

Investors chronicle put out a very interesting article titled Aim traps, very appropriate in regards to all the discussions of recent days.
The following extract caught my eye and I was wondering Moneymunch what your opinion was on it

Online bulletin boards

Bulletin board providers are popular among many private investors – some of whom are incredibly well researched, and some of whom (to put it politely) aren’t. At the lower end of the market, these boards are used to encourage the naïve to buy into a stock. There are many who have multi-IDs who then literally have a conversation with themselves, in an attempt to generate excitement around the stock.

Should anyone post a contrasting opinion – they are called out as a ‘shorter’ or a ‘deramper’ and are the subject of abuse. Worse still, the group encourages everyone to ‘report’ the post in an attempt to have the post automatically deleted. This means that anyone viewing the board will only see one positive narrative because the posts that are automatically deleted are not reviewed by anyone. Those who own the bulletin boards don’t care about the actual content of the posts, because they’re not monetising the boards. What they monetise is the volume of traffic on the site, which they then sell in the form of advertisements and impressions. So, while the bulletin boards are free to use, there is almost no point in using them.

aTyr Pharma (LIFE, aTyr Pharma, has a focus on inflammatory disease. Its leading drug candidate, ATYR1923, is a Neuropilin-2 (NRP2) agonist, working through the receptor proteins expressed by the NRP2 gene. These pathways are important for cardiovascular development and disease, and play a role in the inflammatory lung disease pulmonary sarcoidosis.

In December, the company reported that the drug candidate had completed enrollment of 36 patients in a Phase 1b/2a clinical trial, testing the drug in the treatment of pulmonary sarcoidosis. Results of the current study are expected in 3Q21, and will inform further trials of ATYR1923, including against other forms of inflammatory lung disease.

On a more immediate note, in early January the company announced top-line results of another Phase 2 clinical involving ATRY1923 – this time in the treatment of patients hospitalized with severe respiratory complications from COVID-19. The results were positive, showing that a single dose of ATYR1923 (at 3 mg/kg) resulted in a 5.5-day median recovery time. Overall, of the patients dosed in this manner, 83% saw recovery in less than one week.

Covering LIFE for Roth Capital, 5-star analyst Zegbeh Jallah noted, “We like the risk profile here, with two shots on goal, and updated data details from the COVID study is expected in the coming months. Also announced recently, is that data from aTyr's Pulmonary Sarcoidosis program, will be reported in 3Q21… the success of either of these studies could result in a doubling or more of the market cap as these opportunities appear to barely be accounted for by investors.”

Early March

TheThinker - Similar to yourself I'm looking at these as a potential investment. Rather than focusing on the results due, I'm looking at them as a potential takeover target. With the market cap at 4.24 bn and the value of their properties nearing the 10bn, they could well be a target.
Share price wise, they are definitely nearer to their lows compared to either Tesco or Sainsburys, could well be down to Schroders unwinding some of their position. Also talk of them being ejected from the ft100 which would more then likely have a negative short term impact.
Definitely worth considering.

Read the title, new shareholders

If I'd been allowed to participate in the placement at 8p, I'd be creating an equal short position via spreadex at 10p plus locking in a minimum 25% return. Obviously from a management perspective I would spin the line that we have new investors on board and just how successful its all been, all on the pretence of keeping the price and liquidity up for long enough to unwind the position all to the detriment of the ordinary shareholders.
Wake up people your being played.

My post seems to have disappeared, here it is again for those that missed it.Lots of posts again Moneymunch, same recycled garbage.I was going through my posts and can confirm that I was the first to predict a share placement 3 months ago.Got the usual tirade of abuse from Moneymunch, but thats to be expected from him/her.I'm sorry to have to say this, but I really dont see this company getting anywhere near investors hopeful expectations.It been a dog of a company from day one, who's only real attribute seems to be creating enough excitement to keep investors hooked on what could be, by making out its a possible cure for all things from autism to cancer and anything else they can think of between now and the next funding ( snake oil comes to mind).The reality is that most drugs work at a preclinical stage that is why we have a 95% failure rate when they advance further along. The funding has just secured the 8 employees salaries soon to be 10 for the next 4 years, profit making opportunities to the market makers and fees for their advisors all at the detriment of the ordinary share holder. Its a scam based on science that will not work in the real world hence minimal take up of shares from management. The current trials will prove a failure and then onto the next, only people not making money are the shareholders.This is my personal opinion, I hope I'm completely wrong and the share get to £1 + especially for all those long term investors who have stuck with them.

Really disappointed with the tactics used by management over the last month or so, a few people have made comments referring to the AIM market as the Wild West, I didn't really get it at the time, but having witnessed a CEO blatantly trying to manipulate the share price up for the sole purpose of a share placement it is now clear to me what they mean. Lack of trust in the management and them hardly contributing any of their own money is not a good recipe for an investment.
I hope you all at least make your money back but sadly I cant see it somehow
Good luck

Good luck to you all.

The Directors are asking investors for 11 million pounds but are only prepared to invest £15,000 of their own money. Clearly believe in their product.

Well the sellers clearly got the heads up months ago, off loaded at 11p plus and are now picking them up at 8p all to the detriment of the ordinary share holder. No wonder they are over subscribed, clearly management were in bed with the market makers, poor form, but nothing that wasn't expected.

If I were holding more then 4000 shares outside an isa wrapper, I would seriously be thinking of selling at this point. I think a lot of amateur investors out there have just focused on the dividend, thinking its a free lunch. Once reality sets in, we could well see a sell off.